High-affinity IgE receptor (FcεRI) (FcεRI)

The High-affinity IgE receptor (FcεRI) is a multi-subunit transmembrane protein primarily expressed on mast cells and basophils, where it serves as the key initiator of Type I hypersensitivity reactions. In individuals sensitized to ragweed, the receptor is loaded with ragweed-specific IgE antibodies; upon subsequent exposure, ragweed pollen allergens (such as the major allergen Amb a 1) cross-link these IgE-FcεRI complexes [UniProt, https://www.uniprot.org/uniprotkb/P12319/entry]. This cross-linking event triggers a signaling cascade involving tyrosine kinases like Lyn and Syk, leading to the rapid release of preformed mediators such as histamine and the synthesis of leukotrienes and cytokines [PubMed, https://pubmed.ncbi.nlm.nih.gov/24507031/]. These mediators are responsible for the clinical manifestations of seasonal allergic rhinitis (hay fever) and can contribute to the exacerbation of allergic asthma. Therapeutic interventions targeting this pathway include anti-IgE monoclonal antibodies like omalizumab, which sequester free IgE to prevent its binding to FcεRI and subsequently reduce receptor density on effector cells [DrugBank, https://go.drugbank.com/drugs/DB00038]. Additionally, allergen-specific immunotherapy (AIT) using ragweed extracts like Ragwitek aims to induce immunological tolerance by promoting the production of IgG4 blocking antibodies and regulatory T cells [FDA, https://www.fda.gov/media/88333/download].

Other names

FCER1FceRIHigh affinity immunoglobulin epsilon receptorIgE receptor type IRagweed allergen-IgE-FcεRI complexAmb a 1-IgE-FcεRI complex

The primary mechanism involves preventing the interaction between IgE and the FcεRI receptor or inducing immunological tolerance. Anti-IgE monoclonal antibodies like omalizumab bind to the Cε3 domain of free IgE, preventing it from docking onto FcεRI on mast cells and basophils [DrugBank, https://go.drugbank.com/drugs/DB00038]. This sequestration also leads to the downregulation of FcεRI expression on the cell surface. Allergen-specific immunotherapy (AIT) using ragweed extracts works by inducing regulatory T cells (Tregs) and IgG4 "blocking" antibodies that compete with IgE for allergen binding, thereby preventing the cross-linking of FcεRI and subsequent mediator release [FDA, https://www.fda.gov/media/88333/download].